Table 2 Characteristics of patients with falling pembrolizumab drug level and rising anti-drug antibody level.

From: Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma

Patient Sex Age (years) Stage Pembrolizumab level B/L (ng/μL) Pembrolizumab level T1 (ng/μL) Pembrolizumab level T2 (ng/μL) ADA level B/L (ng/μL) ADA level T1 (ng/μL) ADA level T2 (ng/μL) Progression at 6 months
1 M 66 4 0 469 375 0 2 5 Partial response
2 M 75 4 0 361 272 5 0 7 No Progression
3 F 72 4 0 434 359 0 0 3 No Progression